Stem definition | Drug id | CAS RN |
---|---|---|
SMO receptor antagonists | 4227 | 879085-55-9 |
None
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 4 | Hosey CM, Chan R, Benet LZ |
Vd (Volume of distribution) | 0.23 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 0.01 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.01 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 245 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
July 12, 2013 | EMA | Roche Registration Ltd | |
Jan. 30, 2012 | FDA | GENENTECH |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Muscle spasms | 450.94 | 34.57 | 192 | 2554 | 122921 | 46560395 |
Alopecia | 409.13 | 34.57 | 195 | 2551 | 162219 | 46521097 |
Dysgeusia | 367.24 | 34.57 | 123 | 2623 | 40368 | 46642948 |
Ageusia | 289.51 | 34.57 | 77 | 2669 | 11395 | 46671921 |
Weight decreased | 114.16 | 34.57 | 96 | 2650 | 210753 | 46472563 |
Decreased appetite | 106.40 | 34.57 | 89 | 2657 | 193747 | 46489569 |
Death | 105.53 | 34.57 | 113 | 2633 | 335435 | 46347881 |
Squamous cell carcinoma | 59.74 | 34.57 | 21 | 2725 | 7815 | 46675501 |
Fatigue | 56.17 | 34.57 | 115 | 2631 | 608582 | 46074734 |
Basal cell carcinoma | 52.12 | 34.57 | 25 | 2721 | 20462 | 46662854 |
Nausea | 36.41 | 34.57 | 105 | 2641 | 687349 | 45995967 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Muscle spasms | 964.38 | 34.51 | 348 | 3613 | 64490 | 29884027 |
Alopecia | 760.36 | 34.51 | 218 | 3743 | 19057 | 29929460 |
Ageusia | 619.54 | 34.51 | 158 | 3803 | 8795 | 29939722 |
Dysgeusia | 516.00 | 34.51 | 172 | 3789 | 24629 | 29923888 |
Weight decreased | 180.86 | 34.51 | 153 | 3808 | 150768 | 29797749 |
Squamous cell carcinoma | 161.63 | 34.51 | 58 | 3903 | 10192 | 29938325 |
Decreased appetite | 117.18 | 34.51 | 120 | 3841 | 149790 | 29798727 |
Basal cell carcinoma | 91.69 | 34.51 | 44 | 3917 | 16024 | 29932493 |
Death | 80.33 | 34.51 | 157 | 3804 | 357126 | 29591391 |
Fatigue | 77.03 | 34.51 | 145 | 3816 | 320528 | 29627989 |
Taste disorder | 55.93 | 34.51 | 20 | 3941 | 3463 | 29945054 |
Madarosis | 48.26 | 34.51 | 10 | 3951 | 214 | 29948303 |
Constipation | 47.35 | 34.51 | 66 | 3895 | 112840 | 29835677 |
Myalgia | 40.12 | 34.51 | 50 | 3911 | 76617 | 29871900 |
Hypogeusia | 39.65 | 34.51 | 11 | 3950 | 831 | 29947686 |
Nausea | 37.10 | 34.51 | 104 | 3857 | 296853 | 29651664 |
Source | Code | Description |
---|---|---|
ATC | L01XJ01 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Hedgehog pathway inhibitors |
FDA MoA | N0000184148 | Smoothened Receptor Antagonists |
FDA EPC | N0000184149 | Hedgehog Pathway Inhibitor |
CHEBI has role | CHEBI:35610 | cytostatic |
CHEBI has role | CHEBI:50905 | teratogen |
CHEBI has role | CHEBI:66908 | smoothened antagonist |
CHEBI has role | CHEBI:140921 | hedgehog pathway inhibitor |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Basal cell carcinoma of skin | indication | 254701007 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 10.07 | acidic |
pKa2 | 4.25 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Smoothened homolog | GPCR | INHIBITOR | Ki | 7.79 | CHEMBL | CHEMBL | |||
Sonic hedgehog protein | Enzyme | IC50 | 7.82 | CHEMBL | |||||
Sonic hedgehog protein | Enzyme | IC50 | 8.52 | CHEMBL | |||||
Smoothened homolog | GPCR | IC50 | 8.30 | CHEMBL |
ID | Source |
---|---|
D09992 | KEGG_DRUG |
4031330 | VANDF |
C3265872 | UMLSCUI |
CHEBI:66903 | CHEBI |
VIS | PDB_CHEM_ID |
CHEMBL473417 | ChEMBL_ID |
C538724 | MESH_SUPPLEMENTAL_RECORD_UI |
24776445 | PUBCHEM_CID |
9311 | INN_ID |
25X868M3DS | UNII |
6975 | IUPHAR_LIGAND_ID |
DB08828 | DRUGBANK_ID |
1242987 | RXNORM |
187095 | MMSL |
28293 | MMSL |
d07824 | MMSL |
014152 | NDDF |
703812008 | SNOMEDCT_US |
703813003 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
ERIVEDGE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50242-140 | CAPSULE | 150 mg | ORAL | NDA | 31 sections |